InvestSMART

Imugene Limited (ASX:IMU)

ALERT: Price-sensitive ASX Announcement for IMU
Current share price for IMU : $0.140 0.03 (27.27%)+
Announcement
Release
30 Apr 2026 11:29AM
Price at Release
$0.110
Full Release
download
Summary
Imugene Limited, a clinical-stage immuno-oncology company, provided an update for the quarter ended 31 March 2026. The company reported positive results from its Phase 1b azer-cel clinical trial for the CAR T-naive cohort, including a 100% overall response rate in CLL/SLL and 80% in MZL. The trial protocol was amended to include a BTKi combination arm and Mantle Cell Lymphoma. Imugene received an R&D tax refund of A$2.74 million for the 2025 financial year. The company also raised $16 million through capital raising and announced that azer-cel data would be presented at the ASCO 2026 conference. Imugene's financials included a net cash usage of A$9.67 million in operating activities for the quarter, with R&D comprising 76% of these expenses. The company held an extraordinary general meeting on 23 April 2026 to approve various financial and strategic initiatives.
Key Points
  • Positive results from Phase 1b azer-cel clinical trial.
  • 100% overall response rate in CLL/SLL and 80% in MZL.
  • Azer-cel Phase 1b trial protocol amended to include BTKi combination.
  • Received R&D tax refund of A$2.74 million for 2025.
  • Raised $16 million through capital raising.
  • Azer-cel data selected for ASCO 2026 presentation.
  • Net cash used in operating activities for the quarter was A$9.67 million.
  • Extraordinary general meeting held on 23 April 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.